Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
about
Molecularly targeted drugs for metastatic colorectal cancerStroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitorsCombination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activityA plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancerCD147 monoclonal antibody mediated by chitosan nanoparticles loaded with α-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells.Alternate dosing of cetuximab for patients with metastatic colorectal cancer.Comparison of Neuroprotective Effect of Bevacizumab and Sildenafil following Induction of Stroke in a Mouse Model.Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer.Controlling escape from angiogenesis inhibitors.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma.A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment.Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer.Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept.Therapeutic strategies against cancer stem cells in human colorectal cancer.MiR-93-5p enhances growth and angiogenesis capacity of HUVECs by down-regulating EPLIN.Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels.The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway.Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis.
P2860
Q26828735-A0431C5E-2A30-4C24-B538-CAA273CF5331Q33888739-9ABB97BE-0294-4391-9BBF-3A18FA4C7F07Q33916673-33F2C09B-E255-48E5-9636-3381E081E8B4Q35604265-5C527592-CB92-413C-B5C6-D6AE12959A39Q36333585-3FD98A49-75C1-41D5-AC09-4827A53AD788Q36350566-752C3212-84F0-45CD-B293-4197A27678F6Q36907279-4C6E6B82-9E83-4B74-B925-7687C1AACED5Q36995042-4EE41F87-0F90-4481-8B33-979FC23B355BQ37530472-4A8DA0EC-8DFE-49ED-BCC9-64ACCC9F5112Q37561000-743DB5D6-7646-4404-B56E-B72C9187BFEDQ37672654-9F44E6A1-E088-454D-8F7B-C0E780207461Q38643555-5A1830F3-3503-4F5A-9316-03A5115EDA0CQ39126225-D5788AF2-1C9C-4ED8-B45B-B790ECD3803CQ41483502-EFBEC673-1CDF-4FC6-A7F5-D01D0A4DAA4AQ41590928-4880A7D1-2F78-4E53-B1D5-39B78D779C65Q41608501-0DD44139-67A0-44CE-ADCC-7B43C1D9ED71Q41696836-0132F340-65B1-4803-B3CC-4025FDF2F42EQ42224034-BE181C16-5916-40C6-A87C-9DCD482C6C77Q42775518-E3206E82-A99A-424A-8268-52C3B505C1B9Q47149854-032D9897-0F42-47C3-893A-4C81B9BD4C34Q47241146-1D0028A0-BB6C-41BA-B5F8-626CA0905B19Q51748036-795712AE-5EF6-40B0-BA11-C4B4B67E781DQ54312897-697B6220-55CB-4F69-9C9E-541B1CF3E370Q54979523-82F812BD-1A51-4002-8AC8-9DCB5FA09243Q55502779-2886344C-6C0F-49CE-A791-0DC3BB81FA6D
P2860
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@ast
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@en
type
label
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@ast
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@en
prefLabel
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@ast
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@en
P2860
P1433
P1476
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
@en
P2093
Herbert I Hurwitz
John H Strickler
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0003
P577
2012-04-03T00:00:00Z